Pasireotide
Pasireotide is a pharmaceutical drug with 31 clinical trials. Currently 2 active trials ongoing. Historical success rate of 92.0%.
Success Metrics
Based on 23 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
16
Mid Stage
7
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
82.1%
23 of 28 finished
17.9%
5 ended early
2
trials recruiting
31
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Pasireotide in People With Prolactinoma
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
Clinical Trials (31)
A Study of Pasireotide in People With Prolactinoma
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
Pasireotide Treatment for Neuroendocrine Tumor
Pasireotide in Prevention of GI Toxicity
Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
SOM230 Ectopic ACTH-producing Tumors
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 31